Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Free Research Reports on CLSN, CREE, HALO and TSO Issued by the Bedford Report

IMNN, HALO
Free Research Reports on CLSN, CREE, HALO and TSO Issued by the Bedford Report
http://media.marketwire.com/attachments/201211/53317_equitynewscircuit-logo-final.jpghttp://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1004540&ProfileId=051205&sourceType=1

NEW YORK, NY -- (Marketwired) -- 04/08/13 -- The Bedford Report has released new equity reports today. As a leading provider of free in depth reports and timely market updates, Bedford is an essential resource for hundreds of thousands of investors across the country.

Celsion Corporation (NASDAQ: CLSN) shares of the biotech company have fallen nearly 90 percent year-to-date. The company earlier this year announced that its liver cancer treatment, ThermoDox, failed to meet its primary endpoint of the Phase III HEAT Study.

Find out more about Celsion including full access to the free equity report at: www.BedfordReport.com/CLSN

Cree, Inc. (NASDAQ: CREE) shares have gained approximately 45 percent year-to-date. The company last month raised its revenue target for the third quarter of fiscal 2013. Revenues are now expected to be in the range of $335 million to $350 million.

Find out more about Cree including full access to the free equity report at: www.BedfordReport.com/CREE

Halozyme Therapeutics, Inc. (NASDAQ: HALO) shares have declined approximately 20 percent year-to-date. The company and Baxter International Inc. have recently announced that the European Medicines Agency's CHMP has granted a Positive Opinion for the use of HyQvia as a treatment for primary and secondary immunodeficiencies.

Find out more about Halozyme Therapeutics including full access to the free equity report at: www.BedfordReport.com/HALO

Tesoro Corporation (NYSE: TSO) shares declined 5.02 percent on volume of 6.67 million shares traded Wednesday to close at $52.26 a share. Refiners have fallen sharply in the past week on concerns that new standards proposed by the Environmental Protection Agency would pile on additional costs.

Find out more about Tesoro including full access to the free equity report at: www.BedfordReport.com/TSO

Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. A third party, Providence Media Strategies LLC has paid Equity News Circuit five hundred dollars for the publication of this news release. Neither Equity News Circuit, nor the hiring party, has a financial relationship with any company whose stock is mentioned in this release. Neither Equity News Circuit nor the hiring party are a registered investment advisor, and nothing in this report is intended as a solicitation to buy or sell any security.

Contact Information:

Equity News Circuit
Email Contact



Get the latest news and updates from Stockhouse on social media

Follow STOCKHOUSE Today